Kelk, E.; Ruuge, P.; Rohtla, K.; Poksi, A.; Kairemo, K.
Radiomics Analysis for 177Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer—A Model Based on Clinical Example. Life 2021, 11, 170.
https://doi.org/10.3390/life11020170
AMA Style
Kelk E, Ruuge P, Rohtla K, Poksi A, Kairemo K.
Radiomics Analysis for 177Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer—A Model Based on Clinical Example. Life. 2021; 11(2):170.
https://doi.org/10.3390/life11020170
Chicago/Turabian Style
Kelk, Eve, Priit Ruuge, Kristi Rohtla, Anne Poksi, and Kalevi Kairemo.
2021. "Radiomics Analysis for 177Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer—A Model Based on Clinical Example" Life 11, no. 2: 170.
https://doi.org/10.3390/life11020170
APA Style
Kelk, E., Ruuge, P., Rohtla, K., Poksi, A., & Kairemo, K.
(2021). Radiomics Analysis for 177Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer—A Model Based on Clinical Example. Life, 11(2), 170.
https://doi.org/10.3390/life11020170